Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
Clinical trial NCT07561892 · RECRUITING
Trial details
- NCT number
- NCT07561892
- Sponsor
- Fujian Medical University Union Hospital
- Status
- RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-01
- Primary completion
- 2026-12-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.